[go: up one dir, main page]

CO6260099A2 - Depsipeptidos ciclicos - Google Patents

Depsipeptidos ciclicos

Info

Publication number
CO6260099A2
CO6260099A2 CO10017551A CO10017551A CO6260099A2 CO 6260099 A2 CO6260099 A2 CO 6260099A2 CO 10017551 A CO10017551 A CO 10017551A CO 10017551 A CO10017551 A CO 10017551A CO 6260099 A2 CO6260099 A2 CO 6260099A2
Authority
CO
Colombia
Prior art keywords
derivative
ahp
isoleucine
valine
amino acid
Prior art date
Application number
CO10017551A
Other languages
English (en)
Inventor
Philipp Krastel
Brigitta-Maria Liechty
Josef Gottfried Meingassner
Esther Schmitt
Erwin Paul Schreiner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38805728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6260099(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6260099A2 publication Critical patent/CO6260099A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Un depsipéptido cíclico, o un derivado del mismo, que tiene la estructura de la fórmula (I):en donde se forma un enlace éster entre un grupo carboxilo de A7 y un grupo hidroxilo de A2, en donde X y A1 cada uno independientemente es opcional, y en donde X es cualquier residuo químico, A1 es un aminoácido estándar que no es ácido aspártico; A2 es treonina o serina, A3 es un aminoácido estándar no básico o un derivado no básico del mismo, A4 es Ahp, deshidro-AHP, prolina, o un derivado de los mismos A5 es isoleucina o valina, A6 es tirosina o un derivado de la misma, A7 es leucina, isoleucina o valina, o una sal farmacéuticamente aceptable del mismo. 2.- El depsipéptido cíclico, o un derivado del mismo, de la reivindicación 1 en donde el átomo de nitrógeno del enlace amida entre A5 y A6 se sustituye con un metilo. 3.- El depsipéptido cíclico, o derivado del mismo, de cualquiera de las reivindicaciones 1 o 2 en donde X es H o un residuo acilo.
CO10017551A 2007-08-17 2010-02-16 Depsipeptidos ciclicos CO6260099A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114507 2007-08-17

Publications (1)

Publication Number Publication Date
CO6260099A2 true CO6260099A2 (es) 2011-03-22

Family

ID=38805728

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10017551A CO6260099A2 (es) 2007-08-17 2010-02-16 Depsipeptidos ciclicos

Country Status (30)

Country Link
US (2) US8178650B2 (es)
EP (1) EP2183273B1 (es)
JP (1) JP5520824B2 (es)
KR (2) KR20120123579A (es)
CN (1) CN103298827B (es)
AR (1) AR068343A1 (es)
AU (1) AU2008290567B2 (es)
BR (1) BRPI0815547B8 (es)
CA (1) CA2696570C (es)
CL (1) CL2008002394A1 (es)
CO (1) CO6260099A2 (es)
CR (1) CR11251A (es)
CU (2) CU23943B1 (es)
EA (1) EA017735B1 (es)
EC (1) ECSP109968A (es)
ES (1) ES2632392T3 (es)
GT (1) GT201000037A (es)
MA (1) MA31701B1 (es)
MX (1) MX2010001849A (es)
MY (1) MY151973A (es)
NZ (1) NZ583284A (es)
PE (2) PE20091007A1 (es)
PL (1) PL2183273T3 (es)
PT (1) PT2183273T (es)
SV (1) SV2010003485A (es)
TN (1) TN2010000074A1 (es)
TW (1) TW200922613A (es)
UA (1) UA98658C2 (es)
WO (1) WO2009024527A1 (es)
ZA (1) ZA201000776B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183270B1 (en) 2007-08-17 2014-12-17 Novartis AG Use of cyclic depsipeptides to inhibit kallikrein 7
KR20120123579A (ko) 2007-08-17 2012-11-08 노파르티스 아게 시클릭 뎁시펩티드
EA020118B1 (ru) * 2009-02-13 2014-08-29 Новартис Аг Молекула нуклеиновой кислоты биосинтетического кластера, кодирующая нерибосомальные пептидсинтазы, и ее применение
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US8614289B2 (en) * 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) * 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) * 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
PL3097084T3 (pl) 2014-01-23 2021-02-22 Sixera Pharma Ab Nowe inhibitory kalikreiny 7
WO2015114144A1 (en) * 2014-02-03 2015-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of netherton syndrome
CN106029684A (zh) 2014-04-08 2016-10-12 诺华股份有限公司 用于生产大环缩酚酸肽和新中间体的新型缩醛类方法
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR101729848B1 (ko) 2015-06-30 2017-04-24 영남대학교 산학협력단 신규한 해양 바실러스속 균주, 이로부터 분리한 화합물 및 상기 화합물의 약제학적 용도
CN106518880B (zh) * 2015-11-04 2018-10-19 衡阳师范学院 激肽释放酶7小分子抑制剂及其制备方法与用途
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2020018888A1 (en) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use
AR119997A1 (es) 2019-09-18 2022-01-26 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043252C2 (de) 1980-11-15 1982-12-02 Degussa Ag, 6000 Frankfurt Cyclische Acetale von N-Acylglutaminsäure -γ- semialdehyden, Verfahren zu deren Herstellung und ihre Verwendung
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE4421113A1 (de) * 1994-06-16 1995-12-21 Biotechnolog Forschung Gmbh Chondramide, Gewinnungsverfahren, Mittel mit Chondramiden und Mischkultur zur Chondramid-Gewinnung
DE19828043A1 (de) 1998-06-24 1999-12-30 Bayer Ag Ektoparasitizide Mittel
JP2000154198A (ja) 1998-11-20 2000-06-06 Nisshin Flour Milling Co Ltd 環状デプシペプチドの固相合成方法及びその中間体
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
US20040110228A1 (en) 2002-04-01 2004-06-10 Mcalpine Shelli R. Combinatorial organic synthesis of unique biologically active compounds
CA2525383C (en) 2003-06-06 2012-03-06 Arexis Ab Use of heterocyclic compounds as scce inhibitors
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP1716248A1 (en) * 2004-02-03 2006-11-02 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 7 (klk7)
CA2651796A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
EP2183270B1 (en) 2007-08-17 2014-12-17 Novartis AG Use of cyclic depsipeptides to inhibit kallikrein 7
KR20120123579A (ko) 2007-08-17 2012-11-08 노파르티스 아게 시클릭 뎁시펩티드
US20110112121A1 (en) 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
KR101004362B1 (ko) 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 TNF-α와 TWEAK 이중 길항제
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
WO2012035468A2 (en) 2010-09-14 2012-03-22 Trima - Israel Pharmaceutical Products Maabarot Ltd. Foamable topical composition
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
IL293156A (en) 2011-01-24 2022-07-01 Anterios Inc Nanoparticle compounds, their formulations, and their use
KR20140003572A (ko) 2011-01-24 2014-01-09 안테리오스, 인코퍼레이티드 나노입자 조성물
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates

Also Published As

Publication number Publication date
US8178650B2 (en) 2012-05-15
EA201000329A1 (ru) 2010-08-30
WO2009024527A1 (en) 2009-02-26
GT201000037A (es) 2012-04-30
AU2008290567A1 (en) 2009-02-26
PT2183273T (pt) 2017-05-22
US20090156472A1 (en) 2009-06-18
KR20120123579A (ko) 2012-11-08
ECSP109968A (es) 2010-03-31
MY151973A (en) 2014-07-31
CU20100032A7 (es) 2011-10-05
PE20091007A1 (es) 2009-08-14
BRPI0815547A2 (pt) 2015-02-10
EP2183273B1 (en) 2017-04-05
KR101227231B1 (ko) 2013-01-28
CL2008002394A1 (es) 2009-05-15
EP2183273A1 (en) 2010-05-12
ZA201000776B (en) 2010-10-27
BRPI0815547B1 (pt) 2020-09-15
KR20100044893A (ko) 2010-04-30
UA98658C2 (uk) 2012-06-11
US20120196790A1 (en) 2012-08-02
AU2008290567B2 (en) 2011-05-12
JP5520824B2 (ja) 2014-06-11
PL2183273T3 (pl) 2017-09-29
PE20141199A1 (es) 2014-09-24
CN103298827A (zh) 2013-09-11
US9127044B2 (en) 2015-09-08
CU20130063A7 (es) 2013-06-28
CA2696570C (en) 2020-12-29
AR068343A1 (es) 2009-11-11
JP2010536731A (ja) 2010-12-02
CR11251A (es) 2010-03-08
ES2632392T3 (es) 2017-09-12
TN2010000074A1 (en) 2011-09-26
MA31701B1 (fr) 2010-09-01
NZ583284A (en) 2012-04-27
MX2010001849A (es) 2010-03-10
EA017735B1 (ru) 2013-02-28
SV2010003485A (es) 2011-03-23
CN103298827B (zh) 2017-05-31
BRPI0815547B8 (pt) 2021-05-25
CU23943B1 (es) 2013-09-27
TW200922613A (en) 2009-06-01
CA2696570A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
CO6260099A2 (es) Depsipeptidos ciclicos
ES2527298T3 (es) Uso de depsipéptidos cíclicos para inhibir calicreína 7
CL2011002016A1 (es) Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc).
ES2568009T3 (es) Procedimiento para la absorción de CO2 a partir de una mezcla gaseosa con un medio de absorción que contiene aminas
AR073689A1 (es) Derivados de azaindazol, antagonistas de receptores ccr1, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y de intermediarios, y uso para tratar enfermedades autoinmunes ,diabetes y alzheimer, entre otras.
UY29702A1 (es) Inhibidores macrocíclicos del virus de hepatitis c
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
CL2012000054A1 (es) Composicion farmaceutica líquida que comprende a) un compuesto derivado de quinoleina-2,4,7,8-sustituida, inhibidor de la serina proteasa ns3 del virus de la hepatitis c (vhc), b) uno o mas lipidos, y c) uno o mas tensioactivos hidrofilos.
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
CL2011002377A1 (es) Compuestos derivados de heterociclos triciclicos fusionados de anillo antraceno y bifenileno, inhibidores de proteína ns5a del virus de hepatitis c (vhc); composicion farmaceutica que los comprende; y uso del compuesto en la preparacion de un medicamento util en el tratamiento de hepatitis c.
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
MX2013007104A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
AR067535A1 (es) Derivados de lactama tetraciclicos
GT200800063A (es) Compuestos para la inhibicion de enzimas
EA200400816A1 (ru) Замещенные аналоги хиназолин-4-иламина в качестве модуляторов капсаицина
AR077144A1 (es) Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos
ECSP066504A (es) Derivados biciclicos [3.1.0] como inhibidores del transportador de glicina
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos
AR081039A1 (es) Inhibidores biciclicos fusionados de quinasa
RU2008129096A (ru) Композиция для лечения волос
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
AR058624A1 (es) Derivados de pirimidina como inhibidores de pirimidin quinasa sustituidos. procesos de obtencion y composiciones farmaceuticas.
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
BR112012017188A8 (pt) composto agonista de mglu2, sua composição farmacêutica e seu uso

Legal Events

Date Code Title Description
FG Application granted